Cargando…

Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma

Our expanding knowledge of immunotherapy for solid tumors has led to an explosion of clinical trials aimed at urothelial carcinoma. The primary strategy is centered on unleashing the immune system by releasing the inhibitory signals propagated by programmed cell death-1 (PD-1) and its ligand program...

Descripción completa

Detalles Bibliográficos
Autores principales:	Faiena, Izak, Cummings, Amy L, Crosetti, Anna M, Pantuck, Allan J, Chamie, Karim, Drakaki, Alexandra
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5789049/ https://www.ncbi.nlm.nih.gov/pubmed/29416316 http://dx.doi.org/10.2147/DDDT.S141491

Ejemplares similares

Distinct PD-L1 binding characteristics of therapeutic monoclonal antibody durvalumab
por: Tan, Shuguang, et al.
Publicado: (2017)

Do Cancer Genetics Impact Treatment Decision Making? Immunotherapy and Beyond in the Management of Advanced and Metastatic Urothelial Carcinoma
por: Hui, Gavin, et al.
Publicado: (2023)

Population Pharmacokinetics of an Anti-PD-L1 Antibody, Durvalumab in Patients with Hematologic Malignancies
por: Ogasawara, Ken, et al.
Publicado: (2019)

Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab
por: Lee, Hyun Tae, et al.
Publicado: (2017)

Identification of characteristics predictive of long-term survival with durvalumab or durvalumab plus tremelimumab in metastatic urothelial carcinoma
por: Alt, Marie, et al.
Publicado: (2023)

Durvalumab for urothelial carcinoma, non-small cell lung cancer
Publicado: (2019)

Optimal PD-L1–high cutoff for association with overall survival in patients with urothelial cancer treated with durvalumab monotherapy
por: Zajac, Magdalena, et al.
Publicado: (2020)

Prevention of erectile dysfunction after radiotherapy for prostate cancer
por: Faiena, Izak, et al.
Publicado: (2014)

Granulomatous myositis induced by anti–PD-1 monoclonal antibodies
por: Uchio, Naohiro, et al.
Publicado: (2018)

Anti-PD-L1 monoclonal antibody for the management of chronic disseminated intravascular coagulation secondary to a urothelial carcinoma: a case report
por: Maiorano, Silvia, et al.
Publicado: (2022)

Multimodal treatments for advanced prostate cancer
por: Faiena, Izak, et al.
Publicado: (2019)

Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer
por: Melisi, Davide, et al.
Publicado: (2021)

Investigation of antibody dependent cellular cytotoxicity as a mechanism of action for a novel anti-PD-L1 monoclonal antibody
por: Boyerinas, Benjamin, et al.
Publicado: (2014)

Durvalumab for the management of urothelial carcinoma: a short review on the emerging data and therapeutic potential
por: Baldini, Capucine, et al.
Publicado: (2019)

The combination of anti-KIR monoclonal antibodies with anti-PD-1/PD-L1 monoclonal antibodies could be a critical breakthrough in overcoming tumor immune escape in NSCLC
por: He, Yayi, et al.
Publicado: (2018)

Immune mediators as predictive biomarkers for anti-PD-1 antibody therapy in urothelial carcinoma
por: Shibata, Yosuke, et al.
Publicado: (2023)

First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors
por: Bendell, Johanna, et al.
Publicado: (2023)

Cytoreductive prostatectomy: Evidence in support of a new surgical paradigm (Review)
por: FAIENA, IZAK, et al.
Publicado: (2014)

A phase II trial of durvalumab and tremelimumab in metastatic, non‐urothelial carcinoma of the urinary tract
por: Sarfaty, Michal, et al.
Publicado: (2020)

Anti-Amyloid Monoclonal Antibodies are Transformative Treatments that Redefine Alzheimer's Disease Therapeutics
por: Cummings, Jeffrey
Publicado: (2023)

Disorder of Coagulation-Fibrinolysis System: An Emerging Toxicity of Anti-PD-1/PD-L1 Monoclonal Antibodies
por: Sato, Ryo, et al.
Publicado: (2019)

Concurrent durvalumab and radiation therapy (DUART) followed by adjuvant durvalumab in patients with localized urothelial cancer of bladder: results from phase II study, BTCRC-GU15-023
por: Joshi, Monika, et al.
Publicado: (2023)

Unusual radiologic manifestation of pseudoprogression in pulmonary metastases after durvalumab treatment in metastatic bladder urothelial cancer
por: Kim, Eun Young, et al.
Publicado: (2019)

Response to Anti-PD1/L1 Antibodies in Advanced Urothelial Cancer in the ‘Real-Life’ Setting
por: Gadot, Moran, et al.
Publicado: (2022)

Seeing is believing: anti-PD-1/PD-L1 monoclonal antibodies in action for checkpoint blockade tumor immunotherapy
por: Tan, Shuguang, et al.
Publicado: (2016)

Overcoming Immune Resistance in Prostate Cancer: Challenges and Advances
por: Movassaghi, Miyad, et al.
Publicado: (2021)

Effectiveness of anti-PD-1/PD-L1 antibodies in urothelial carcinoma patients with different PD-L1 expression levels: a meta-analysis
por: Liu, Junqi, et al.
Publicado: (2018)

A Comparison of Murine PD-1 and PD-L1 Monoclonal Antibodies
por: Bu, Melissa T., et al.
Publicado: (2022)

Discovery and preclinical characterization of the antagonist anti-PD-L1 monoclonal antibody LY3300054
por: Li, Yiwen, et al.
Publicado: (2018)

Highly efficient hybridoma generation and screening strategy for anti-PD-1 monoclonal antibody development
por: Phakham, Tanapati, et al.
Publicado: (2022)

Her-2 Targeted Therapy in Advanced Urothelial Cancer: From Monoclonal Antibodies to Antibody-Drug Conjugates
por: Albarrán, Víctor, et al.
Publicado: (2022)

Population Modeling of Tumor Kinetics and Overall Survival to Identify Prognostic and Predictive Biomarkers of Efficacy for Durvalumab in Patients With Urothelial Carcinoma
por: Zheng, Yanan, et al.
Publicado: (2018)

Correction to: Discovery and preclinical characterization of the antagonist anti-PD-L1 monoclonal antibody LY3300054
por: Li, Yiwen, et al.
Publicado: (2018)

Dying cells expose a nuclear antigen cross-reacting with anti-PD-1 monoclonal antibodies
por: Metzger, Philipp, et al.
Publicado: (2018)

Preclinical characterization of Sintilimab, a fully human anti-PD-1 therapeutic monoclonal antibody for cancer
por: Zhang, Shuang, et al.
Publicado: (2018)

Intravenous Delivery of RNA Encoding Anti-PD-1 Human Monoclonal Antibody for Treating Intestinal Cancer
por: Wu, Lipei, et al.
Publicado: (2022)

Comprehensive Analysis of Nivolumab, A Therapeutic Anti-Pd-1 Monoclonal Antibody: Impact of Handling and Stress
por: Torrente-López, Anabel, et al.
Publicado: (2022)

Anti-PD-1 monoclonal antibody MEDI0680 in a phase I study of patients with advanced solid malignancies
por: Naing, Aung, et al.
Publicado: (2019)

Anti-CGRP Monoclonal Antibodies: the Next Era of Migraine Prevention?
por: Tso, Amy R., et al.
Publicado: (2017)

Results of PD-L1 Analysis of Women Treated with Durvalumab in Advanced Endometrial Carcinoma (PHAEDRA)
por: Smith, Deborah, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_b7nfa8d9qi84bm2nc92m27n48v